Xiu-Ling Luo on Muck Rack

Xiu-Ling Luo

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Xiu-Ling

Contact Xiu-Ling, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study

|
By Ya-Lan Tao, Dong-Hong Wu, Qin Zhou, Kun-Yu Yang, Feng Jin, Xiao-Dong Zhu, Mei Shi, Guo-Qing Hu, Yan Sun, Hong-fen Wu, Hui Wu, Qin Lin, Hui Wang, Ye Tian, Ning Zhang, Xi-Cheng Wang, Liang-Fang Shen, Zheng-zheng Liu, Jing Huang, Jian Zang, Bao-Min Zheng, Dan Yue, Jing Xu, San-Gang Wu, Lei Chen, Wen-Fei Li, Guan-Qun Zhou, Rui Sun, Rui Guo, YUAN ZHANG, Cheng Xu, Jia-Wei Lv, Ying Guo, Ling-Long Tang, Fang-Yun Xie, Xu Liu, Ying Sun, Jun Ma, Yan-Ping Mao, Yu-Pei Chen, Xiu-Ling Luo, Hui-Xia Feng
| Nature Verified
Abstract Here we report long-term outcomes of adjuvant metronomic capecitabine in patients with locoregionally advanced nasopharyngeal carcinoma. In this multicenter, open-label, parallel-group, randomized, controlled, phase 3 trial, 406 patients who had completed definitive chemoradiotherapy were randomly assigned (1:1) to receive either adjuvant metronomic capecitabine (650 mg m−2 twice daily for 1 year) or observation.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified